{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:24:38Z","timestamp":1782753878972,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Panzhihua City Medical Research Center Project","award":["PYYZ-2022\u201313"],"award-info":[{"award-number":["PYYZ-2022\u201313"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06965-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:26:22Z","timestamp":1775031982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of modified dendritic cell\u2013cytokine-induced killer cells loaded with tumour stem cell membrane microparticle therapy in the treatment of relapsed or refractory T- and NK-cell lymphoid proliferations and lymphomas: a report of three cases"],"prefix":"10.1007","volume":"105","author":[{"given":"Ao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"6","key":"6965_CR1","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","volume":"180","author":"A Crinier","year":"2020","unstructured":"Crinier A, Narni-Mancinelli E, Ugolini S, Vivier E (2020) Snapshot: natural killer cells. Cell 180(6):1280. https:\/\/doi.org\/10.1016\/j.cell.2020.02.029","journal-title":"Cell"},{"issue":"1","key":"6965_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, Wang X, Xing P, Jia K et al (2024) Pd-1\/Pd-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer 23(1):266. https:\/\/doi.org\/10.1186\/s12943-024-02176-8","journal-title":"Mol Cancer"},{"issue":"1","key":"6965_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10235-1","volume":"44","author":"EC Smith","year":"2024","unstructured":"Smith EC, Mott BT, Douglas E, Tatter SB, Watabe K (2024) Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities. Cancer Metastasis Rev 44(1):10. https:\/\/doi.org\/10.1007\/s10555-024-10235-1","journal-title":"Cancer Metastasis Rev"},{"key":"6965_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102183","volume":"51","author":"Y Wang","year":"2025","unstructured":"Wang Y, Qi SN, Bi N, Li YX (2025) Flash radiotherapy combined with immunotherapy: from biological mechanisms to blockbuster therapeutics. Transl Oncol 51:102183. https:\/\/doi.org\/10.1016\/j.tranon.2024.102183","journal-title":"Transl Oncol"},{"key":"6965_CR5","doi-asserted-by":"publisher","unstructured":"Zhang Y, Ellinger J, Ritter M, Schmidt-Wolf IGH (2020) Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinom. Cancers (Basel) 12(9). https:\/\/doi.org\/10.3390\/cancers12092471","DOI":"10.3390\/cancers12092471"},{"issue":"1","key":"6965_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a Scid mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139\u201349. https:\/\/doi.org\/10.1084\/jem.174.1.139","journal-title":"J Exp Med"},{"key":"6965_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-1-4939-0856-1_11","volume":"1165","author":"MA Antonyak","year":"2014","unstructured":"Antonyak MA, Cerione RA (2014) Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol 1165:147\u201373. https:\/\/doi.org\/10.1007\/978-1-4939-0856-1_11","journal-title":"Methods Mol Biol"},{"issue":"1","key":"6965_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","volume":"21","author":"M Mathieu","year":"2019","unstructured":"Mathieu M, Martin-Jaular L, Lavieu G, Th\u00e9ry C (2019) Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21(1):9\u201317. https:\/\/doi.org\/10.1038\/s41556-018-0250-9","journal-title":"Nat Cell Biol"},{"issue":"2","key":"6965_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3164\/jcbn.24-240","volume":"77","author":"M Shen","year":"2025","unstructured":"Shen M, Wan S, Yang X, Liu X, Ma L, Liao X (2025) Tumor-derived exosomes containing circ_0008039 promote the stemness of colorectal cancer cells by inhibiting ferroptosis. J Clin Biochem Nutr 77(2):120\u201330. https:\/\/doi.org\/10.3164\/jcbn.24-240","journal-title":"J Clin Biochem Nutr"},{"key":"6965_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04045-6","author":"X Jiang","year":"2026","unstructured":"Jiang X, Song J, Mu Y, Zu G, Wang R, Liu X et al (2026) Microfluidics Engineered Autologous Nanovaccine for Activating and Visualizing Antitumor Activity. J Nanobiotechnology. https:\/\/doi.org\/10.1186\/s12951-026-04045-6. (Epub)","journal-title":"J Nanobiotechnology"},{"key":"6965_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.actbio.2019.04.033","volume":"91","author":"STT Schetters","year":"2019","unstructured":"Schetters STT, Jong WSP, Horrevorts SK, Kruijssen LJW, Engels S, Stolk D et al (2019) Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to Cd8(+) t cells. Acta Biomater 91:248\u201357. https:\/\/doi.org\/10.1016\/j.actbio.2019.04.033","journal-title":"Acta Biomater"},{"key":"6965_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bioactmat.2024.09.002","volume":"42","author":"NT Nguyen","year":"2024","unstructured":"Nguyen NT, Le XT, Lee WT, Lim YT, Oh KT, Lee ES et al (2024) Sting-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy. Bioact Mater 42:345\u201365. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.09.002","journal-title":"Bioact Mater"},{"issue":"1","key":"6965_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100936","volume":"7","author":"X Song","year":"2026","unstructured":"Song X, Lu C, Shi T, Wang H, Liu W, Luo Y et al (2026) Mhc-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors. Med 7(1):100936. https:\/\/doi.org\/10.1016\/j.medj.2025.100936","journal-title":"Med"},{"key":"6965_CR14","doi-asserted-by":"publisher","unstructured":"Ito Y, Ohta S, Kagoya Y (2024) 17 Genetically Engineered Cell-Derived Membrane Vesicles Induce Multifaceted Anti-Tumor Immunity. J Immunother Cancer 12(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0017","DOI":"10.1136\/jitc-2024-SITC2024.0017"},{"issue":"2","key":"6965_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41551-024-01309-0","volume":"9","author":"N Li","year":"2025","unstructured":"Li N, Qin H, Zhu F, Ding H, Chen Y, Lin Y et al (2025) Potent Prophylactic Cancer Vaccines Harnessing Surface Antigens Shared by Tumour Cells and Induced Pluripotent Stem Cells. Nat Biomed Eng 9(2):215\u2013233 Epub 2024\/12\/28. https:\/\/doi.org\/10.1038\/s41551-024-01309-0","journal-title":"Nat Biomed Eng"},{"issue":"14","key":"6965_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202501616","volume":"37","author":"N Krishnan","year":"2025","unstructured":"Krishnan N, Zhou J, Mohapatra A, Ventura CJ, Duan Y, Lee J et al (2025) Universal prophylactic antitumor vaccination using stem cell membrane-coated nanoparticles. Adv Mater 37(14):e2501616. https:\/\/doi.org\/10.1002\/adma.202501616","journal-title":"Adv Mater"},{"issue":"10","key":"6965_CR17","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4240\/wjgs.v16.i10.3202","volume":"16","author":"ZY Ding","year":"2024","unstructured":"Ding ZY, Piao Y, Jiang T, Chen J, Wang YN, Yu HY et al (2024) Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer. World J Gastrointest Surg 16(10):3202\u201310. https:\/\/doi.org\/10.4240\/wjgs.v16.i10.3202","journal-title":"World J Gastrointest Surg"},{"issue":"2","key":"6965_CR18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s12013-024-01569-2","volume":"83","author":"Y Li","year":"2025","unstructured":"Li Y, Chen S, Liu S (2025) Immune effect of co-culture of dendritic cells and cytokine-induced killer cells on prostate cancer cells. Cell Biochem Biophys 83(2):1593. https:\/\/doi.org\/10.1007\/s12013-024-01569-2","journal-title":"Cell Biochem Biophys"},{"issue":"8000","key":"6965_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR (2024) Natural killer cell therapies. Nature 626(8000):727\u201336. https:\/\/doi.org\/10.1038\/s41586-023-06945-1","journal-title":"Nature"},{"issue":"3","key":"6965_CR20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3233\/thc-230871","volume":"32","author":"L Wang","year":"2024","unstructured":"Wang L, Li X, Dong XJ, Yu XL, Zhang J, Cheng ZG et al (2024) Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone. Technol Health Care 32(3):1819\u201334. https:\/\/doi.org\/10.3233\/thc-230871","journal-title":"Technol Health Care"},{"issue":"10","key":"6965_CR21","first-page":"4767","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, Song Y, Shi Q, Qiao G, Zhao Y, Zhou L et al (2023) Safety of Dendritic Cell and Cytokine-Induced Killer (Dc-Cik) Cell-Based Immunotherapy in Patients with Solid Tumor: A Retrospective Study in China. Am J Cancer Res 13(10):4767\u20134782 Epub 2023\/11\/16","journal-title":"Am J Cancer Res"},{"key":"6965_CR22","unstructured":"Fang X, Qiang L, Huanxu G, Xueqian Y, Hui Z, Li L et al (2016) Efficacy of Donor-Derived Cytokine Induced Killer Cells Infusion for Minimal Residual Diseases in Patients after Allogeneic Stem Cell Transplantation. J Third Mil Med Univ"},{"issue":"6","key":"6965_CR23","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","volume":"109","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Vinanica N, Wong DMH, Campana D (2024) Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia. Haematologica 109(6):1677\u201388. https:\/\/doi.org\/10.3324\/haematol.2023.283848","journal-title":"Haematologica"},{"key":"6965_CR24","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.2147\/ijn.S477597","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Nie D, Liu Z, Peng X, Wang X, Qiu K et al (2024) Aptamer Sgc8-Modified Pamam Nanoparticles for Targeted Sirna Delivery to Inhibit Bcl11b in T-Cell Acute Lymphoblastic Leukemia. Int J Nanomed 19:12297\u201312309 Epub 2024\/11\/25. https:\/\/doi.org\/10.2147\/ijn.S477597","journal-title":"Int J Nanomed"},{"issue":"13","key":"6965_CR25","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1080\/10428194.2024.2390567","volume":"65","author":"J Frutos D\u00edaz-Alejo","year":"2024","unstructured":"Frutos D\u00edaz-Alejo J, Morillo-Giles D, D\u00edaz de la Pinta FJ, Manso R, Rodr\u00edguez-Pinilla SM, Rodr\u00edguez M (2024) New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis. Leuk Lymphoma 65(13):2056\u20139. https:\/\/doi.org\/10.1080\/10428194.2024.2390567","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"6965_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM (2017) Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 129(9):1095\u2013102. https:\/\/doi.org\/10.1182\/blood-2016-09-692541","journal-title":"Blood"},{"issue":"9","key":"6965_CR27","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Fu BB, Gale RP, Liang Y (2021) Nk-\/T-cell lymphomas. Leukemia 35(9):2460\u20138. https:\/\/doi.org\/10.1038\/s41375-021-01313-2","journal-title":"Leukemia"},{"issue":"1","key":"6965_CR28","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1093\/oncolo\/oyad241","volume":"29","author":"R Tao","year":"2024","unstructured":"Tao R, Liu C, Zhang W, Zhu Y, Ma Y, Hao S (2024) Selinexor with anti-Pd-1 antibody as a potentially effective regimen for patients with natural killer\/T-cell lymphoma failing prior L-asparaginase and Pd-1 blockade. Oncologist 29(1):e90\u2013e6. https:\/\/doi.org\/10.1093\/oncolo\/oyad241","journal-title":"Oncologist"},{"issue":"1","key":"6965_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse E, Zhao WL, Xiong J, Kwong YL (2022) How we treat Nk\/T-cell lymphomas. J Hematol Oncol 15(1):74. https:\/\/doi.org\/10.1186\/s13045-022-01293-5","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6965_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.19746\/j.cnki.issn.1009-2137.2019.03.056","volume":"27","author":"HS Liu","year":"2019","unstructured":"Liu HS, Shi J, Liu HB, Ma TT, Li XR, Zhang M (2019) [Efficacy of Autologous Dc-Cik Cells Combined with Other Immune Cells in the Treatment of Hematological Malignancies -Retrospective Study]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27(3):983\u201390. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2019.03.056","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"6965_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925633","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu X, Sharma A, Weiher H, Schmid M, Kristiansen G et al (2022) Anti-Cd40 predominates over anti-Ctla-4 to provide enhanced antitumor response of Dc-Cik cells in renal cell carcinoma. Front Immunol 13:925633. https:\/\/doi.org\/10.3389\/fimmu.2022.925633","journal-title":"Front Immunol"},{"issue":"2","key":"6965_CR32","first-page":"334","volume":"7","author":"Z Zhen","year":"2017","unstructured":"Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y et al (2017) Hla-E Inhibitor Enhances the Killing of Neuroblastoma Stem Cells by Co-Cultured Dendritic Cells and Cytokine-Induced Killer Cells Loaded with Membrane-Based Microparticles. Am J Cancer Res 7(2):334\u2013345 Epub 2017\/03\/25","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6965_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger N, Bond D, Jaglowski S (2022) Car T-cell therapy for B-cell lymphoma. Curr Probl Cancer 46(1):100826. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100826","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"6965_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00277-024-06132-w","volume":"104","author":"JF Ma","year":"2025","unstructured":"Ma JF, Yan CL, Jia X, Zhu HJ, Yan JW, Liu MJ et al (2025) Clinical Outcomes and Safety of Car-T Cells in Treatment of T-Cell Acute Lymphoblastic Leukemia\/Lymphoma. Ann Hematol 104(1):57\u201363 Epub 2024\/12\/18. https:\/\/doi.org\/10.1007\/s00277-024-06132-w","journal-title":"Ann Hematol"},{"issue":"13","key":"6965_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2023023443","volume":"143","author":"NS Grover","year":"2024","unstructured":"Grover NS, Beaven AW (2024) T-cell lymphoma: the car-T revolution is coming. Blood 143(13):1201\u20132. https:\/\/doi.org\/10.1182\/blood.2023023443","journal-title":"Blood"},{"key":"6965_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109168","volume":"246","author":"E Roshandel","year":"2023","unstructured":"Roshandel E, Ghaffari-Nazari H, Mohammadian M, Salimi M, Abroun S, Mirfakhraie R et al (2023) Nk cell therapy in relapsed refractory multiple myeloma. Clin Immunol 246:109168. https:\/\/doi.org\/10.1016\/j.clim.2022.109168","journal-title":"Clin Immunol"},{"key":"6965_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V (2023) Advances in Nk cell therapy for hematologic malignancies: Nk source, persistence and tumor targeting. Blood Rev 60:101073. https:\/\/doi.org\/10.1016\/j.blre.2023.101073","journal-title":"Blood Rev"},{"issue":"6","key":"6965_CR38","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M et al (2025) Allogeneic Nk cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(6):1987\u201393. https:\/\/doi.org\/10.1038\/s41591-025-03640-8","journal-title":"Nat Med"},{"key":"6965_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/09636897241231892","volume":"33","author":"J Han","year":"2024","unstructured":"Han J, Zhang B, Zheng S, Jiang Y, Zhang X, Mao K (2024) The progress and prospects of immune cell therapy for the treatment of cancer. Cell Transplant 33:9636897241231892. https:\/\/doi.org\/10.1177\/09636897241231892","journal-title":"Cell Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06965-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:46Z","timestamp":1776405526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06965-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6965"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06965-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the he Affiliated Hospital of Panzhihua University Ethics Committee\/Institutional Review Board (ID: 2023-03-001). Informed consent for participation in the study was obtained directly from all participating adults. For paediatric participants, informed consent was provided by their legal guardians or next of kin. Similarly, informed consent for the publication of the research data and any accompanying images was signed by the adult participants themselves, or by the legal guardians or next of kin of the paediatric participants. Both consents (for participation and for publication) are explicitly differentiated here, even if they were recorded using a single form. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee(s) and with the Helsinki Declaration (as revised in 2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}